These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 36206664)

  • 41. Correction: CUL3/SPOP complex prevents immune escape and enhances chemotherapy sensitivity of ovarian cancer cells through degradation of PD-L1 protein.
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38101867
    [No Abstract]   [Full Text] [Related]  

  • 42. ReSPONDINg TACtically, degrading strategically.
    Zerfas BL; Jones LH
    Trends Pharmacol Sci; 2023 Nov; 44(11):753-754. PubMed ID: 37689534
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Extracellular vesicle surface display of αPD-L1 and αCD3 antibodies via engineered late domain-based scaffold to activate T-cell anti-tumor immunity.
    Chen R; Kang Z; Li W; Xu T; Wang Y; Jiang Q; Wang Y; Huang Z; Xu X; Huang Z
    J Extracell Vesicles; 2024 Jul; 13(7):e12490. PubMed ID: 39051742
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lipid-based nanosystems: the next generation of cancer immune therapy.
    Cheng Z; Fobian SF; Gurrieri E; Amin M; D'Agostino VG; Falahati M; Zalba S; Debets R; Garrido MJ; Saeed M; Seynhaeve ALB; Balcioglu HE; Ten Hagen TLM
    J Hematol Oncol; 2024 Jul; 17(1):53. PubMed ID: 39030582
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nanomedicines: Emerging Platforms in Smart Chemotherapy Treatment-A Recent Review.
    Arafat M; Sakkal M; Beiram R; AbuRuz S
    Pharmaceuticals (Basel); 2024 Feb; 17(3):. PubMed ID: 38543101
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PD-L1 Immune Checkpoint Targeted Photoactivable Liposomes (iTPALs) Prime the Stroma of Pancreatic Tumors and Promote Self-Delivery.
    Bhandari C; Moffat A; Shah N; Khan A; Quaye M; Fakhry J; Soma S; Nguyen A; Eroy M; Malkoochi A; Brekken R; Hasan T; Ferruzzi J; Obaid G
    Adv Healthc Mater; 2024 Jul; 13(19):e2304340. PubMed ID: 38324463
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD-L1 in Cancer Therapy.
    Wang Y; Zhou Y; Yang L; Lei L; He B; Cao J; Gao H
    Adv Sci (Weinh); 2024 Jan; 11(1):e2303175. PubMed ID: 37934012
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Micro-syringe chip-guided intratumoral administration of lipid nanoparticles for targeted anticancer therapy.
    Kim J; Song S; Gwak M; Cho H; Yun WS; Hwang N; Kim J; Lee JS; Kim DH; Kim H; Jeon SI; Kim TI; Kim K
    Biomater Res; 2023 Oct; 27(1):102. PubMed ID: 37845762
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Recent Review on Cancer Nanomedicine.
    Giri PM; Banerjee A; Layek B
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190185
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy.
    Ma GL; Lin WF
    Mil Med Res; 2023 Apr; 10(1):20. PubMed ID: 37106400
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evading Doxorubicin-Induced Systemic Immunosuppression Using Ultrasound-Responsive Liposomes Combined with Focused Ultrasound.
    Lee J; Um W; Moon H; Joo H; Song Y; Park M; Yoon B; Kim HR; Park JH
    Pharmaceutics; 2022 Nov; 14(12):. PubMed ID: 36559097
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy.
    Lee Y; Song S; Yang S; Kim J; Moon Y; Shim N; Yoon HY; Kim S; Shim MK; Kim K
    Acta Pharm Sin B; 2024 Mar; 14(3):1428-1440. PubMed ID: 38487005
    [TBL] [Abstract][Full Text] [Related]  

  • 53. All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy.
    Song S; Shim MK; Yang S; Lee J; Yun WS; Cho H; Moon Y; Min JY; Han EH; Yoon HY; Kim K
    Bioact Mater; 2023 Oct; 28():358-375. PubMed ID: 37334068
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapy.
    Kim J; Shim MK; Moon Y; Kim J; Cho H; Yun WS; Shim N; Seong JK; Lee Y; Lim DK; Kim K
    J Nanobiotechnology; 2024 Mar; 22(1):109. PubMed ID: 38481326
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PD-L1 degradation pathway and immunotherapy for cancer.
    Gou Q; Dong C; Xu H; Khan B; Jin J; Liu Q; Shi J; Hou Y
    Cell Death Dis; 2020 Nov; 11(11):955. PubMed ID: 33159034
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Emerging Interplay Between Recirculating and Tissue-Resident Memory T Cells in Cancer Immunity: Lessons Learned From PD-1/PD-L1 Blockade Therapy and Remaining Gaps.
    Gitto S; Natalini A; Antonangeli F; Di Rosa F
    Front Immunol; 2021; 12():755304. PubMed ID: 34867987
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity.
    Yang S; Shim MK; Song S; Cho H; Choi J; Jeon SI; Kim WJ; Um W; Park JH; Yoon HY; Kim K
    Biomaterials; 2022 Nov; 290():121841. PubMed ID: 36206664
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.